Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BSN antisense RNA 2 (BSN-DT) is a long non-coding RNA gene positioned head-to-head with the protein-coding BSN (Bassoon) gene, transcribed from the opposite strand[3]. Because BSN-DT is a non-coding antisense RNA, it is believed to have regulatory functions, possibly affecting the expression of the adjacent BSN gene, which encodes a synaptic scaffolding protein important in neurotransmitter release and has notable associations with neurological diseases[2][4]. However, direct functional or clinical relevance of BSN-DT itself has not been established, and it is not recognized as a therapeutic target or a molecule with known drug interactions based on current biomedical knowledge[3].\n\nThere are no drugs, biomarkers, or safety concerns currently associated with BSN-DT, and mechanistic information is lacking. The bulk of research and clinical interest in this genomic locus centers on the BSN protein and not its divergent non-coding transcripts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BSN antisense RNA 2 (BSN-DT).